Last updated: January 1, 2025 | Effective date: January 1, 2025
Welcome to nuclivision.co. These Terms of Use ("Terms") constitute a legally binding agreement between you ("you" or "user") and NucliVision Inc. ("NucliVision", "we", "us", "our"), a Delaware corporation headquartered in Boston, Massachusetts. These Terms govern your access to and use of the NucliVision website located at nuclivision.co and any subdomains thereof (collectively, the "Site").
By accessing or using the Site, you acknowledge that you have read, understood, and agree to be bound by these Terms. If you do not agree with any part of these Terms, you must immediately discontinue use of the Site.
These Terms apply to all visitors, registered users, healthcare professionals, institutional representatives, investors, journalists, and anyone else who accesses or uses the Site.
Your access to and use of the Site is conditioned upon your acceptance of and compliance with these Terms. These Terms apply to all visitors, users, and others who access or use the Site. By accessing the Site, you represent and warrant that:
NucliVision reserves the right to modify these Terms at any time. We will provide notice of material changes by updating the "Last updated" date at the top of this page. Your continued use of the Site following the posting of revised Terms means you accept and agree to the changes.
The Site provides informational content about NucliVision Inc. and its AI-based nuclear medicine imaging software platform. Content published on the Site includes:
Subject to these Terms, NucliVision grants you a limited, non-exclusive, non-transferable, revocable license to access and use the Site for your personal, non-commercial, informational purposes. Permitted uses include:
You agree not to use the Site for any of the following purposes:
The content published on this Site is for general informational purposes only and does not constitute medical advice, clinical guidance, diagnostic recommendations, treatment protocols, or regulatory opinion of any kind.
Nuclear medicine imaging is a specialized medical discipline. Decisions regarding patient imaging, scan interpretation, dosimetry, treatment planning, and clinical management must be made exclusively by qualified, licensed healthcare professionals with appropriate training and access to the full clinical context of each patient case.
NucliVision's AI software products, including image enhancement, dosimetry calculation, and reporting assistance tools, are intended for use by trained nuclear medicine physicians, nuclear medicine technologists, medical physicists, and other qualified clinical personnel. These products are medical devices and must be used in accordance with their intended use, indications for use, contraindications, and instructions for use as specified in the applicable product documentation.
Nothing on this Site should be construed as a representation that any NucliVision product is appropriate for use in any specific clinical situation, patient population, or institution. Clinical suitability must be evaluated by qualified clinical personnel on a case-by-case basis.
NucliVision's nuclear medicine AI software products are medical devices subject to regulation by the U.S. Food and Drug Administration (FDA) under 21 CFR Part 820 and related regulations. As of the date of these Terms:
References to regulatory activities on this Site (including FDA pre-submission meetings, 510(k) submission timelines, and CE marking pathways) reflect NucliVision's current plans and should not be construed as representations that specific regulatory outcomes will be achieved by specific dates. Regulatory timelines are subject to FDA review processes and may change.
For the most current regulatory status, contact NucliVision at [email protected].
The Site and its entire contents, features, and functionality — including but not limited to all text, graphics, photographs, illustrations, videos, logos, icons, audio clips, digital downloads, data compilations, software, and the design, selection, and arrangement thereof — are owned by NucliVision, its licensors, or other providers of such material and are protected by United States and international copyright, trademark, patent, trade secret, and other intellectual property laws.
The NucliVision name, the NucliVision logo, and all related names, logos, product and service names, designs, and slogans are trademarks of NucliVision Inc. or its affiliates. You must not use such marks without the prior written permission of NucliVision. All other names, logos, product and service names, designs, and slogans on this Site are the trademarks of their respective owners.
You may print or download one copy of a reasonable number of pages of the Site for your own personal, non-commercial, informational use, provided you do not modify the materials and you retain all copyright, trademark, and other proprietary notices. You may not:
If you submit comments, questions, feedback, or other content to NucliVision through the Site (including through contact forms), you grant NucliVision a non-exclusive, perpetual, royalty-free license to use, reproduce, modify, and publish such content for internal business purposes, including improving our products and services. You represent and warrant that you own or have the right to submit all content you provide to us.
THE SITE IS PROVIDED ON AN "AS IS" AND "AS AVAILABLE" BASIS, WITHOUT ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED. NUCLIVISION EXPRESSLY DISCLAIMS ALL WARRANTIES, INCLUDING BUT NOT LIMITED TO IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE, AND NON-INFRINGEMENT.
NucliVision does not warrant that:
Information published on the Site about nuclear medicine AI, clinical evidence, regulatory pathways, and company milestones is provided for general informational purposes and may not reflect the most current developments. We make no representations about the suitability or applicability of the information for any particular clinical or regulatory situation.
TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, IN NO EVENT SHALL NUCLIVISION INC., ITS AFFILIATES, DIRECTORS, OFFICERS, EMPLOYEES, AGENTS, LICENSORS, OR SERVICE PROVIDERS BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL, EXEMPLARY, OR PUNITIVE DAMAGES, INCLUDING BUT NOT LIMITED TO LOSS OF PROFITS, LOSS OF DATA, LOSS OF GOODWILL, SERVICE INTERRUPTION, COMPUTER DAMAGE, SYSTEM FAILURE, OR THE COST OF SUBSTITUTE SERVICES, ARISING OUT OF OR IN CONNECTION WITH THESE TERMS OR YOUR USE OF THE SITE, WHETHER BASED ON WARRANTY, CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY, OR ANY OTHER LEGAL THEORY, EVEN IF NUCLIVISION HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
TO THE EXTENT NOT PROHIBITED BY LAW, NUCLIVISION'S TOTAL LIABILITY TO YOU FOR ALL CLAIMS ARISING FROM OR RELATED TO THE SITE SHALL NOT EXCEED ONE HUNDRED DOLLARS ($100.00).
Some jurisdictions do not allow the exclusion or limitation of certain types of liability. In such jurisdictions, our liability shall be limited to the maximum extent permitted by law.
You agree to defend, indemnify, and hold harmless NucliVision Inc. and its affiliates, licensors, and service providers, and its and their respective officers, directors, employees, contractors, agents, licensors, suppliers, successors, and assigns from and against any claims, liabilities, damages, judgments, awards, losses, costs, expenses, or fees (including reasonable attorneys' fees) arising out of or relating to:
The Site may contain links to third-party websites, publications, databases, and resources, including medical journal articles, conference proceedings, FDA guidance documents, and professional society resources. These links are provided as a convenience and for informational purposes only. NucliVision does not endorse the content of any third-party site and has no control over the content, privacy policies, or practices of any third-party websites.
You acknowledge and agree that NucliVision is not responsible or liable for any content, advertising, products, or other materials on or available from third-party sites. We encourage you to review the terms and privacy policies of any third-party site you visit.
NucliVision reserves the right to terminate or suspend your access to the Site at any time, without prior notice or liability, for any reason, including if we believe you have violated these Terms. Upon termination, your right to use the Site will immediately cease.
Provisions of these Terms that by their nature should survive termination shall survive termination, including ownership provisions, warranty disclaimers, indemnification obligations, and limitations of liability.
Before filing a formal claim, you agree to first contact NucliVision at [email protected] and attempt to resolve the dispute informally. NucliVision will attempt to resolve the dispute informally by contacting you via email. If a dispute is not resolved within 30 days, either party may proceed to formal dispute resolution.
Any dispute, controversy, or claim arising out of or relating to these Terms, or the breach, termination, or invalidity thereof, shall be settled by binding arbitration administered by the American Arbitration Association (AAA) under its Commercial Arbitration Rules. The arbitration shall take place in Boston, Massachusetts, unless the parties mutually agree to an alternative location or to conduct the arbitration by remote means. The arbitrator's award shall be final and binding on the parties.
YOU AND NUCLIVISION AGREE THAT EACH MAY BRING CLAIMS AGAINST THE OTHER ONLY IN YOUR OR ITS INDIVIDUAL CAPACITY, AND NOT AS A PLAINTIFF OR CLASS MEMBER IN ANY PURPORTED CLASS OR REPRESENTATIVE PROCEEDING. Unless both you and NucliVision agree otherwise, no arbitrator may consolidate more than one person's claims or may otherwise preside over any form of a representative or class proceeding.
Either party may seek emergency injunctive or other equitable relief in a court of competent jurisdiction to preserve the status quo pending arbitration, or to protect intellectual property rights. Nothing in this section prevents NucliVision from seeking injunctive relief to prevent irreparable harm in connection with unauthorized use of our intellectual property.
These Terms and any dispute arising hereunder are governed by and construed in accordance with the laws of the Commonwealth of Massachusetts, United States, without regard to its conflict of law provisions. For any disputes not subject to arbitration under Section 11, you consent to the exclusive jurisdiction of the state and federal courts located in Suffolk County, Massachusetts.
If you are accessing the Site from outside the United States, you are responsible for compliance with local laws. You agree that regardless of any statute or law to the contrary, any claim or cause of action arising out of or related to use of the Site or these Terms must be filed within one year after such claim or cause of action arose or be forever barred.
If any provision of these Terms is found by a court or arbitrator of competent jurisdiction to be invalid, illegal, or unenforceable, that provision shall be modified to the minimum extent necessary to make it enforceable, and the remaining provisions shall continue in full force and effect.
NucliVision's failure to enforce any right or provision of these Terms shall not constitute a waiver of such right or provision. A waiver of any default shall not be a waiver of any subsequent default.
These Terms, together with our Privacy Policy and Cookie Policy, constitute the entire agreement between you and NucliVision with respect to the Site and supersede all prior and contemporaneous agreements, understandings, negotiations, and discussions, whether oral or written, between you and NucliVision.
For healthcare institutions and partners who have entered into separate agreements with NucliVision (including evaluation agreements, pilot agreements, or commercial contracts), those agreements govern to the extent they conflict with these Terms.
If you have questions about these Terms or need to contact us for any reason related to your use of the Site:
NucliVision Inc.
Avenue Louise 523, 1050 Brussels, Belgium
United States
[email protected]
+32 2 880 4210
For legal notices or formal correspondence, please mark communications "Attn: Legal" and send to the address above.